2018 Q3 Form 10-Q Financial Statement
#000143774918021015 Filed on November 16, 2018
Income Statement
| Concept | 2018 Q3 | 2017 Q3 | 2016 Q4 |
|---|---|---|---|
| Revenue | $260.3K | $162.2K | $160.0K |
| YoY Change | 60.47% | -8.25% | -90.06% |
| Cost Of Revenue | $44.86K | $264.0K | $280.0K |
| YoY Change | -83.01% | -4.9% | -75.86% |
| Gross Profit | $215.4K | -$101.8K | -$110.0K |
| YoY Change | -311.62% | 0.96% | -124.44% |
| Gross Profit Margin | 82.77% | -62.76% | -68.75% |
| Selling, General & Admin | $531.7K | $973.9K | $1.910M |
| YoY Change | -45.4% | -31.97% | -29.0% |
| % of Gross Profit | 246.83% | ||
| Research & Development | $95.49K | $299.5K | $470.0K |
| YoY Change | -68.12% | -7.41% | -32.86% |
| % of Gross Profit | 44.32% | ||
| Depreciation & Amortization | $25.00K | $51.00K | $320.0K |
| YoY Change | -50.98% | -83.55% | 52.38% |
| % of Gross Profit | 11.61% | ||
| Operating Expenses | $627.2K | $1.273M | $2.380M |
| YoY Change | -50.74% | -27.44% | -29.79% |
| Operating Profit | -$411.8K | -$1.375M | -$2.490M |
| YoY Change | -70.06% | -25.9% | -15.31% |
| Interest Expense | -$18.25K | -$3.900K | $0.00 |
| YoY Change | 368.03% | 268.27% | -100.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$238.1K | -$1.724K | $10.00K |
| YoY Change | 13709.98% | -97.17% | -100.03% |
| Pretax Income | -$649.9K | -$1.380M | -$2.480M |
| YoY Change | -52.91% | -28.0% | -94.14% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$649.9K | -$1.377M | -$2.480M |
| YoY Change | -52.8% | -28.16% | -94.13% |
| Net Earnings / Revenue | -249.68% | -848.91% | -1550.0% |
| Basic Earnings Per Share | -$0.03 | -$0.09 | |
| Diluted Earnings Per Share | -$0.03 | -$0.09 | -$0.24 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 23.72M | 15.85M | 9.927M shares |
| Diluted Shares Outstanding | 23.72M | 15.85M |
Balance Sheet
| Concept | 2018 Q3 | 2017 Q3 | 2016 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $250.2K | $1.920M | $2.620M |
| YoY Change | -86.97% | -50.52% | 184.78% |
| Cash & Equivalents | $250.2K | $1.923M | $2.620M |
| Short-Term Investments | |||
| Other Short-Term Assets | $75.05K | $420.0K | $380.0K |
| YoY Change | -82.13% | -46.15% | -55.29% |
| Inventory | $34.07K | $64.14K | $69.95K |
| Prepaid Expenses | |||
| Receivables | $254.6K | $160.0K | $290.0K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $613.8K | $2.568M | $3.372M |
| YoY Change | -76.1% | -54.27% | 10.6% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $130.7K | $255.9K | $486.1K |
| YoY Change | -48.93% | -62.97% | -56.41% |
| Goodwill | $0.00 | $2.079M | |
| YoY Change | -100.0% | ||
| Intangibles | $7.201M | $7.840M | |
| YoY Change | 211.95% | ||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $15.32K | $188.1K | $278.7K |
| YoY Change | -91.86% | -39.32% | -29.66% |
| Total Long-Term Assets | $146.0K | $7.645M | $10.68M |
| YoY Change | -98.09% | -31.33% | 165.46% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $613.8K | $2.568M | $3.372M |
| Total Long-Term Assets | $146.0K | $7.645M | $10.68M |
| Total Assets | $759.8K | $10.21M | $14.06M |
| YoY Change | -92.56% | -39.02% | 98.72% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $481.0K | $434.5K | $392.6K |
| YoY Change | 10.71% | -12.81% | -63.2% |
| Accrued Expenses | $314.5K | $1.251M | $1.055M |
| YoY Change | -74.86% | 3.19% | -57.01% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $16.67K | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | ||
| YoY Change | -100.0% | ||
| Total Short-Term Liabilities | $1.342M | $1.686M | $1.447M |
| YoY Change | -20.4% | -1.47% | -96.57% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $58.99K | $123.4K | |
| YoY Change | -58.8% | -59.8% | |
| Total Long-Term Liabilities | $0.00 | $58.99K | $123.4K |
| YoY Change | -100.0% | -58.8% | -86.93% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $1.342M | $1.686M | $1.447M |
| Total Long-Term Liabilities | $0.00 | $58.99K | $123.4K |
| Total Liabilities | $1.342M | $1.745M | $1.571M |
| YoY Change | -23.09% | -5.9% | -96.36% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$22.59M | -$12.68M | -$5.696M |
| YoY Change | 78.16% | -96.5% | |
| Common Stock | $2.372K | $2.273K | $993.00 |
| YoY Change | 4.36% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$581.8K | $8.469M | $12.49M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $759.8K | $10.21M | $14.06M |
| YoY Change | -92.56% | -39.02% | 98.72% |
Cashflow Statement
| Concept | 2018 Q3 | 2017 Q3 | 2016 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$649.9K | -$1.377M | -$2.480M |
| YoY Change | -52.8% | -28.16% | -94.13% |
| Depreciation, Depletion And Amortization | $25.00K | $51.00K | $320.0K |
| YoY Change | -50.98% | -83.55% | 52.38% |
| Cash From Operating Activities | -$441.1K | -$1.410M | -$1.360M |
| YoY Change | -68.71% | -35.62% | -50.36% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | |||
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $2.000K | $0.00 | $100.0K |
| YoY Change | 150.0% | ||
| Cash From Investing Activities | $2.000K | $0.00 | $100.0K |
| YoY Change | -125.64% | ||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $3.000M | ||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 315.8K | 3.000M | 0.000 |
| YoY Change | -89.47% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -441.1K | -1.410M | -1.360M |
| Cash From Investing Activities | 2.000K | 0.000 | 100.0K |
| Cash From Financing Activities | 315.8K | 3.000M | 0.000 |
| Net Change In Cash | -123.3K | 1.590M | -1.260M |
| YoY Change | -107.76% | -172.6% | -59.74% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$441.1K | -$1.410M | -$1.360M |
| Capital Expenditures | |||
| Free Cash Flow | |||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q3 | aurx |
Authorized Shares Common And Preferred
AuthorizedSharesCommonAndPreferred
|
101000000 | |
| CY2018Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
314482 | |
| aurx |
Debt Discount Warrants
DebtDiscountWarrants
|
18624 | ||
| aurx |
Debt Discount Warrants
DebtDiscountWarrants
|
|||
| CY2018Q3 | aurx |
Fair Value Adjustment Of Derivatives
FairValueAdjustmentOfDerivatives
|
234824 | |
| CY2017Q3 | aurx |
Fair Value Adjustment Of Derivatives
FairValueAdjustmentOfDerivatives
|
||
| aurx |
Fair Value Adjustment Of Derivatives
FairValueAdjustmentOfDerivatives
|
234824 | ||
| aurx |
Fair Value Adjustment Of Derivatives
FairValueAdjustmentOfDerivatives
|
|||
| CY2017Q2 | aurx |
Goodwill Carrying Amount Exceeding Fair Value
GoodwillCarryingAmountExceedingFairValue
|
2800000 | |
| aurx |
Issuance Of Options To Settle Accrued Compensation Liabilities
IssuanceOfOptionsToSettleAccruedCompensationLiabilities
|
321250 | ||
| aurx |
Issuance Of Options To Settle Accrued Compensation Liabilities
IssuanceOfOptionsToSettleAccruedCompensationLiabilities
|
|||
| CY2018Q3 | aurx |
Percentage Of Revenues Generated Outside Of United States
PercentageOfRevenuesGeneratedOutsideOfUnitedStates
|
0.75 | |
| CY2017Q3 | aurx |
Percentage Of Revenues Generated Outside Of United States
PercentageOfRevenuesGeneratedOutsideOfUnitedStates
|
0.25 | |
| aurx |
Percentage Of Revenues Generated Outside Of United States
PercentageOfRevenuesGeneratedOutsideOfUnitedStates
|
0.52 | ||
| aurx |
Percentage Of Revenues Generated Outside Of United States
PercentageOfRevenuesGeneratedOutsideOfUnitedStates
|
0.27 | ||
| aurx |
Recognition Of Derivative Liabilities Related To Convertible Debt
RecognitionOfDerivativeLiabilitiesRelatedToConvertibleDebt
|
532000 | ||
| aurx |
Recognition Of Derivative Liabilities Related To Convertible Debt
RecognitionOfDerivativeLiabilitiesRelatedToConvertibleDebt
|
|||
| CY2018Q3 | us-gaap |
Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
|
254553 | |
| CY2017Q4 | us-gaap |
Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
|
114331 | |
| CY2018Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
481000 | |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
380280 | |
| CY2018Q3 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
256528 | |
| CY2017Q4 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
420226 | |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
556557 | |
| CY2018Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
593050 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
538724 | |
| CY2018Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
22000902 | |
| CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
21155404 | |
| CY2018Q3 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
2000 | |
| CY2017Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
306000 | |
| CY2018Q3 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
1975 | |
| CY2017Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
305895 | |
| CY2018Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
|
240000 | |
| us-gaap |
Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
|
240000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
16667 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
|||
| CY2018Q3 | us-gaap |
Assets
Assets
|
759839 | |
| CY2017Q4 | us-gaap |
Assets
Assets
|
1424039 | |
| CY2018Q3 | us-gaap |
Assets Current
AssetsCurrent
|
613839 | |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1185107 | |
| CY2018Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
250171 | |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
693515 | |
| CY2017Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1923172 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2620023 | |
| CY2018Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
250171 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
693515 | |
| CY2017Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
1973180 | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2673526 | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-443344 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-700346 | ||
| CY2018Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2018Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2018Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
31500000 | |
| CY2018Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23722400 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22722400 | |
| CY2018Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23722400 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22722400 | |
| CY2018Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
2372 | |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2272 | |
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Credit Concentration</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">We generate accounts receivable from the sale of our product. In addition, other receivables consist primarily of (i) a receivable for the royalty buyout by the licensee of Aldeflour as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018, </div>and (ii) royalties due for sales of Aldeflour and a settlement amount for a prior value added tax receivable due from the contract manufacturer of the prior Angel product line as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017. </div>Customers or other receivables balances in excess of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of total receivables at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>were as follows:</div> <div style=" margin: 0pt 30pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 18pt; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 68%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer A</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer B</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">76</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </table> </div> <div style=" margin: 0pt 30pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Revenue from significant customers exceeding <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of total revenues for the periods presented was as follows:</div> <div style=" margin: 0pt 30pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 18pt; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">ended </div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">ended </div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 68%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer A</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer B</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer C</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </table> </div> <div style=" margin: 0pt 30pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 18pt; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine</div><div style="display: inline; font-weight: bold;"> Months</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">ended </div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine</div><div style="display: inline; font-weight: bold;"> Months</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">ended </div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-weight: bold;"> 30,</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 68%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer A</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer B</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </table> </div> <div style=" margin: 0pt 30pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Historically, we have used single suppliers for several components of the Aurix product line. We outsource the manufacturing of various product components to contract manufacturers. While we believe these manufacturers demonstrate competency, reliability and stability, there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more of them will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experience an interruption or inability to provide us with the products needed to satisfy customer demand. Additionally, while most of the components of Aurix are generally readily available on the open market, a reagent, bovine thrombin, is available exclusively through Pfizer, with whom we have an established vendor relationship.</div></div></div></div> | ||
| CY2018Q3 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
16667 | |
| CY2017Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
||
| CY2018Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
44856 | |
| CY2017Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
263993 | |
| us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
132083 | ||
| us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
811451 | ||
| CY2018Q3 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
44856 | |
| CY2017Q3 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
263993 | |
| us-gaap |
Cost Of Revenue
CostOfRevenue
|
132083 | ||
| us-gaap |
Cost Of Revenue
CostOfRevenue
|
811451 | ||
| CY2018Q2 | us-gaap |
Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
|
0 | |
| us-gaap |
Depreciation
Depreciation
|
77000 | ||
| us-gaap |
Depreciation
Depreciation
|
230000 | ||
| CY2018Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
25000 | |
| CY2017Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
51000 | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
76994 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
868570 | ||
| CY2018Q3 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
528003 | |
| CY2017Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
||
| CY2018Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.03 | |
| CY2017Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.09 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.08 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.59 | ||
| CY2018Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.03 | |
| CY2017Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.09 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.08 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.59 | ||
| CY2018Q3 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
3997 | |
| CY2017Q3 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
||
| us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
3997 | ||
| us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
|||
| us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
-13938 | ||
| us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
1205 | ||
| CY2018Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
514876 | |
| CY2017Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
811034 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1496138 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3058046 | ||
| CY2017Q2 | us-gaap |
Goodwill
Goodwill
|
0 | |
| us-gaap |
Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
|
|||
| us-gaap |
Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
|
2079284 | ||
| us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
2100000 | ||
| CY2018Q3 | us-gaap |
Gross Profit
GrossProfit
|
215424 | |
| CY2017Q3 | us-gaap |
Gross Profit
GrossProfit
|
-101797 | |
| us-gaap |
Gross Profit
GrossProfit
|
426449 | ||
| us-gaap |
Gross Profit
GrossProfit
|
-287912 | ||
| us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
0 | ||
| us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
0 | ||
| us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
|||
| us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
|||
| us-gaap |
Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
|
-99438 | ||
| us-gaap |
Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
|
-227785 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
100720 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
41852 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
79175 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
118866 | ||
| us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
1506 | ||
| us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
|||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
4940 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-718 | ||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
|||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-90625 | ||
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-4331 | ||
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-64440 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-266622 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
33047 | ||
| CY2018Q3 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-18253 | |
| CY2017Q3 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-3900 | |
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-18620 | ||
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-11738 | ||
| us-gaap |
Interest Paid Net
InterestPaidNet
|
|||
| us-gaap |
Interest Paid Net
InterestPaidNet
|
9812 | ||
| CY2018Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
1506 | |
| CY2017Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
||
| CY2018Q3 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
30000 | |
| CY2017Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
40000 | |
| CY2018Q3 | us-gaap |
Inventory Net
InventoryNet
|
34066 | |
| CY2017Q4 | us-gaap |
Inventory Net
InventoryNet
|
35590 | |
| CY2018Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-238084 | |
| CY2017Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1724 | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-248104 | ||
| CY2018Q3 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
20000 | |
| CY2017Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
18000 | |
| CY2018Q3 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
16000 | |
| CY2017Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
23000 | |
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
6464 | ||
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
5101 | ||
| CY2018Q3 | us-gaap |
Liabilities
Liabilities
|
1341658 | |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
941168 | |
| CY2018Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
759839 | |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1424039 | |
| CY2018Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1341658 | |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
936837 | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> – Description of Business and Bankruptcy Proceedings</div></div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Description of Business</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Nuo Therapeutics, Inc. (“Nuo Therapeutics,” the “Company,” “we,” “us,” or “our”) is a biomedical company marketing its products primarily within the U.S. We commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The use of autologous (from self) biological therapies for tissue repair and regeneration is part of a transformative clinical strategy designed to improve long term recovery in complex chronic conditions with significant unmet medical needs.</div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Currently, our commercial offering consists solely of the Aurix point of care technology for the safe and efficient separation of autologous blood to produce a platelet based therapy for the chronic wound care market. Prior to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 5, 2016 (</div>the “Effective Date”), the effective date of the Company’s emergence from bankruptcy under a confirmed Plan of Reorganization (See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div>), we had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> distinct platelet rich plasma (“PRP”) devices: the Aurix® System for wound care, and the Angel® concentrated Platelet Rich Plasma (“cPRP”) System for orthopedics markets. Prior to the Effective Date, Arthrex, Inc. (“Arthrex”) was our exclusive distributor for Angel. Pursuant to the Plan of Reorganization, on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 5, 2016, </div>the Company assigned its rights, title and interest in and to the existing license agreement with Arthrex to Deerfield Management Company, L.P. and its affiliates (“Deerfield”), as well as rights to collect royalty payments thereunder.</div></div> | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
815800 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3000000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
1914 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
2000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1261144 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-3702260 | ||
| CY2018Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-649878 | |
| CY2017Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1376899 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-1910288 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-6981560 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-10693 | ||
| us-gaap |
Number Of Reporting Units
NumberOfReportingUnits
|
1 | ||
| CY2018Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
627218 | |
| CY2017Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
1273378 | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
2088633 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
6682955 | ||
| CY2018Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-411794 | |
| CY2017Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1375175 | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1662184 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6970867 | ||
| CY2018Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
15316 | |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
15316 | |
| CY2018Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
||
| CY2017Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
4331 | |
| CY2018Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
10996 | |
| CY2017Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2176 | |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1343 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1045 | ||
| CY2018Q3 | us-gaap |
Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
|
29038000 | |
| CY2017Q4 | us-gaap |
Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
|
29038000 | |
| CY2018Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
29038 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
29038 | |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
29038 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
29038 | |
| CY2018Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
3 | |
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
3 | |
| CY2018Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
75049 | |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
341671 | |
| us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Reclassifications</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Certain reclassification have been made to the prior year financial statements to conform to the current year presentation, including the addition of restricted cash to cash and cash equivalents on the consolidated statements of cash flows as a result of the adoption of new accounting guidance.</div></div></div></div> | ||
| us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
315800 | ||
| us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
|||
| CY2017Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3000000 | |
| CY2018Q2 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
500000 | |
| CY2018Q2 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
500000 | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
500000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3000000 | ||
| us-gaap |
Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
|
2000 | ||
| us-gaap |
Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
|
1914 | ||
| CY2018Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
723734 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
762340 | |
| CY2018Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
130684 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
223616 | |
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
-239660 | ||
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
-97115 | ||
| CY2018Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
95486 | |
| CY2017Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
299477 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
493588 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1008377 | ||
| CY2018Q3 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
||
| CY2017Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
||
| CY2017Q3 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
50008 | |
| CY2016Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
53503 | |
| CY2018Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-22585096 | |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-20674808 | |
| CY2018Q3 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
260280 | |
| CY2017Q3 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
162196 | |
| us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
558532 | ||
| us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
523539 | ||
| CY2018Q3 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
16856 | |
| CY2017Q3 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
162867 | |
| us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
98907 | ||
| us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
537248 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5724 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
42306 | ||
| CY2018Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1370 | |
| CY2017Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
14335 | |
| us-gaap |
Stock Issued1
StockIssued1
|
|||
| us-gaap |
Stock Issued1
StockIssued1
|
77500 | ||
| CY2017Q3 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
12800000 | |
| CY2018Q2 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
1000000 | |
| CY2018Q2 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
1000000 | |
| CY2018Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-581819 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
482871 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, stock-based compensation, allowance for inventory obsolescence, allowance for doubtful accounts, contingent liabilities, fair value and depreciable lives of long-lived assets (including property and equipment, intangible assets and goodwill), deferred taxes and associated valuation allowance and the classification of our long-term debt. Actual results could differ from those estimates.</div></div></div></div> | ||
| CY2018Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
23722400 | |
| CY2017Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
15852764 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
23128993 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
11924035 | ||
| CY2018Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
23722400 | |
| CY2017Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
15852764 | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
23128993 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
11924035 |
